Effect Of Semaglutide In Coronary Atheroma Plaque
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT05071417
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 120 participants
- Sponsor
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
- Registry
-
NCT05071417
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05071417. Allocation not applicable; no masking; primary purpose treatment. Start 2021-11 (anticipated); primary completion 2024-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect Of Semaglutide In Coronary Atheroma Plaque
- Acronym
- SEPLA
- Condition
- Atheroscleroses, Coronary
- Intervention (Drug)
- Semaglutide
- Lead sponsor
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Record details
- Record id
cardio:ct-nct05071417- Content hash
6e7e32540677e24131445da601f0c587c6a72b993e29896eb249fe3ee099dfe3